reports
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Update: Initial orders point to start of commercialisation
Rex Bionics, a pioneer in the medical exoskeleton field, has recently reported a number of encouraging updates, including interim financial results, new distributors for the key US and China markets and positive interim metrics from its RAPPER II clinical trial. The company is focused on rehabilitating and improving mobility in patients with spinal cord injury. Its two key markets are rehabilitation centres and home use. Clinical trials demonstrating the medical benefits to patients and commerci...
Flash note: RAPPER II first cohort generates positive results
Rex Bionics' RAPPER II clinical trial interim data were presented at the Australia and New Zealand Spinal Cord Society meeting last week. Trial interim results show that the Rex unit is safe for patient use. Positive RAPPER II results are expected to facilitate the company’s commercialisation strategy for the Rex exoskeleton. We will revisit our forecasts following H1 results in December.
Update: RAPPER II trial off to a good start
RAPPER II is a 100-patient study to measure the time taken for wheelchair users to mobilise in a Rex unit and complete an exercise regime. The study also intends to provide a better understanding of the severity of injury that can be safely treated with a Rex unit. The first patient has successfully completed the assessment and the data from the first cohort of patients are expected to be presented before the end of 2015. Trials such as this and RAPPER I, are key to driving adoption and therefor...
Initiation: The Robotic physiotherapist
Rex Bionics is a pioneer in the field of medical exoskeletons. It is focused on rehabilitating and improvement in the mobility of patients with spinal cord injury. Its two key markets are rehabilitation centres and home use. Fourteen devices are currently in use, but clinical trials demonstrating the medical benefits to patients and commercial benefits to rehab centres has recently been initiated; with promising data from the first trial. A reverse DCF implies growth in sales to only 207 units b...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.